biotech · Uveal Melanoma · Choroidal Melanoma · AURA
Aura Biosciences
Aura Biosciences is a biotech organization headquartered in Boston, USA. It trades on NYSE under ticker AURA. Primary therapeutic focus areas include Uveal Melanoma, Choroidal Melanoma, Primary Indeterminate Lesions or S
Boston, USA HQ
2009 Founded
128 Employees
Public company Type
AURA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boston, USA
- Founded
- 2009
- Employees
- 128
- Programs
- 6
- Drugs
- 3
- Patents
- 17
AU-011
Phase 2 · small molecule · Uveal Melanoma
AU-011 for Uveal Melanoma is a Phase 2 program (small_molecule) at Aura Biosciences with 1 ClinicalTrials.gov record(s).
Internal code AU-011-202
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Aura Biosciences
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Uveal Melanoma
- Status
- completed
- Trials
- 1